Kirenol alleviates Th2-driven allergic asthma by modulating T-cell responses.

Area of Science:

• Immunology
• Pharmacology
• Allergy Research

Background:

• Allergic asthma is primarily driven by type 2 T helper (Th2) immune responses.
• Understanding the mechanisms underlying Th2-driven inflammation is crucial for developing effective asthma therapies.

Purpose of the Study:

• To investigate the therapeutic potential and underlying mechanisms of kirenol (Kr) in a mouse model of ovalbumin (OVA)-induced allergic asthma.
• To elucidate how Kr modulates T-cell responses, particularly Th2 polarization and proliferation.

Main Methods:

• Ovalbumin (OVA)-induced asthma model in mice treated orally with kirenol (Kr).
• In vitro studies using anti-CD3/CD28-stimulated CD4+ T cells treated with Kr.
• Analysis of immune cell counts, cytokine levels (IL-4, IL-5, IL-13, IL-2, IFN-γ), IgE production, airway hyperresponsiveness, mucus production, gene expression (GATA3), and T-cell activation markers.
• Transcriptomic analysis of T cells and immunomodulatory effect on dendritic cells.

Main Results:

• Kr treatment significantly reduced OVA-specific IgE, airway hyperresponsiveness, Th2 cytokines, and chemokines in asthmatic mice.
• Kr attenuated lung inflammation, inflammatory cell recruitment, and mucus production.
• In vitro, Kr suppressed CD4+ T cell proliferation by arresting cell cycle, decreased Th2 cytokine secretion, and inhibited Th2 polarization by downregulating GATA3 expression.
• Kr reduced T-cell activation markers and influenced immune-related gene expression without affecting dendritic cell function.

Conclusions:

• Kirenol demonstrates significant therapeutic potential for allergic asthma by modulating Th2-mediated immune responses.
• Kr effectively regulates CD4+ T cell proliferation, activation, and differentiation, offering a promising approach for asthma treatment.